netFormulary NHS
North Staffordshire Joint Formulary
North Staffordshire Clinical Commissioning Group
Stoke-on-Trent Clinical Commissioning Group
 Search
 Formulary Chapter 11: Eye - Full Chapter
11.06  Expand sub section  Treatment of glaucoma
11.06  Expand sub section  Beta-blockers
Betaxolol hydrochloride
(Betoptic)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Betoptic®- Betaxolol hydrochloride 0.25% eye drops
Betoptic®- Betaxolol hydrochloride 0.25 % eye drops (0.25ml Unit Doses) - P/free
Betoptic®- Betaxolol hydrochloride 0.5% eye drops

 
   
Carteolol (Teoptic)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted

Carteolol 1% eye drops
Carteolol 2% eye drops

DISCONTINUED 2017

 
   
Timolol maleate 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Timolol maleate 0.25% eye drops
Timolol maleate 0.5% eye drops
Timolol maleate 0.1% eye gel
Timolol maleate 0.5% eye gel (Timoptol-LA)
Timolol maleate 0.25% and 0.5% eye drops (0.2ml unit doses)- P/free

 

 

 
   
11.06  Expand sub section  Prostaglandin analogues
Latanoprost 
View adult BNF View SPC online View childrens BNF  Track Changes
First Choice
Amber

Latanoprost 50microgram/ml eye drops

1st line Prostaglandin analogue

 

 
Bimatoprost 
View adult BNF View SPC online View childrens BNF  Track Changes
Second Choice
Amber

Lumigan®- Bimatoprost 100microgam/ml eye drops
Bimatoprost 300microgam/ml eye drops
Bimatoprost 300 micrograms/ml eye drops (0.4ml unit dose) - P/free

2nd line prostaglandin analogue after Latanoprost

 

 
   
Travoprost 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Travoprost 40microgram/ml eye drops

 
   
Bimatoprost with timolol
(Ganfort)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

2nd line after latanoprost & timolol eye drops

Ganfort®- Bimatoprost 300microgram/ml & Timolol 5mg/ml eye drops

 
   
Latanoprost with timolol

View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Latanoprost 50microgram/ml & Timolol 5mg/ml eye drops

 
   
Tafluprost with timolol
(Taptiqom)
(Preservative free)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

1st line in patients who cannot tolerate a preservative-containing prostaglandin analogue/beta-blocker combination product

Taptiqom®- Tafluprost 15microgram/ml & Timolol 5mg/ml eye drops (0.3ml unit dose) - P/free

 
   
Bimatoprost with timolol
(Ganfort)
(Preservative free)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Ganfort®- Bimatoprost 300microgram/ml & Timolol 5mg/ml eye drops (0.4ml unit dose) - P/free

 
   
11.06  Expand sub section  Sympathomimetics
Brimonidine tartrate

View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Brimonidine tartrate 0.2% eye drops

 
   
11.06  Expand sub section  Carbonic anhydrase inhibitors and systemic drugs to top
Acetazolamide 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Acetazolamide 250mg tablets
Acetazolamide SR 250mg capsules

 

 
   
Azarga (Brinzolamide 1% & timolol 0.5% )
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Azarga®- Brinzolamide 1% & timolol 0.5% eye drops

Restriction: Initiation by Consultant Ophthalmologist only

 

 
   
Brinzolamide 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Brinzolamide 10mg/ml eye drops

 
   
Dorzolomide hydrochloride

View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Dorzolomide hydrochloride 20mg/ml eye drops
Trusopt®- Dorzolomide hydrochloride 20mg/ml eye drops (0.2ml unit dose) P/free

 
   
Simbrinza
(Brinzolamide 10mg/ml & brimonidine 2mg/ml)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Simbrinza®- Brinzolamide 10mg/ml & brimonidine 2mg/ml eye drops

 
   
11.06  Expand sub section  Miotics
Pilocarpine hydrochoride

View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Pilocarpine hydrochoride 1% eye drops
Pilocarpine hydrochoride 2% eye drops
Pilocarpine hydrochoride 4% eye drops

 
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG
Blueteq
High Cost Drug Approval System

Traffic Light Status Information

Status Description

Red

Medicines that can only be prescribed within Secondary Care. Examples of medicines which fall into this category are: Certain new medicines and new indications for older medicines where there is at present no experience of use in Primary Care. Medicines or dressings not available or prescribable in Primary Care. Where a medicine has been classified as Amber E, but an approved shared-care guideline is not yet available   

Amber

Medicines which can be prescribed within Secondary Care, but are only suitable for prescribing in Primary Care after specialist referral. There is no need for approved shared care guidelines for medicines in this category. This replaces Amber 2 on the North Staffs Formulary.   

Amber E

Medicines which can be prescribed within Secondary Care, but are only considered suitable for prescribing in Primary Care under an approved shared-care agreement (ESCA) or Rationale for Initiation, Continuation and Discontinuation (RICaD). This replaces Amber 1 on the North Staffs Formulary  

Green

Medicines which can be prescribed in either Primary or Secondary Care.  

Grey

These medicines have been reviewed by the New Medicines Committee and the Area Prescribing Committee and found not to be suitable for inclusion in the Joint Formulary. Inadequate or weak evidence for efficacy No clearly defined local need Lack of long term safety data No perceived benefit over established formulary alternatives Prescribers can consider these medicines where formulary alternatives are unsuitable, ineffective or not tolerated.  

netFormulary